Lewis Silkin has advised Norstella on disposal of Clinerion to form a strategic partnership with TriNetX

Founded in 2022, Norstella unites market-leading pharmaceutical solutions providers that have a shared goal of helping patients gain access to life-saving therapies. Clinerion, with corporate entities in Switzerland and Turkey, are known for a research network spanning more than 75 healthcare organisations across 25 countries, leveraging pseudonymized real-world data to support data-driven clinical trial optimization and real-world evidence (RWE) generation.

The strategic partnership between Norstella and TriNetX (now with Clinerion as part of its network) will allow Norstella to leverage the global research network and enhance their portfolio of products and services for its life sciences customers.

The Lewis Silkin team was led by Corporate Partner, Sam Pennington, with Corporate support from Legal Director - Francesca Ainsworth and Associate - Ayesha Chanda. The team also included Commercial Managing Associate – JJ Shaw, Tax Partner - Matthew Rowbotham and Tax Senior Associate Emma McGrory.

Commenting on the deal, Lewis Silkin’s Sam Pennington said:

Our team were pleased to support life sciences client Norstella with an efficient and collaborative process to achieve the sale of Clinerion, and we look forward to watching the development of the strategic partnership between Norstella and TriNetX go from strength to strength.

Commenting on the deal, Norstella's General Counsel, Vicky Harris said:

At Norstella we are very happy to partner with TriNetX to support our customers with access to real world data to help with making better decisions and advancing our mission to help patients get access to lifesaving treatments. The Lewis Silkin team proved a trusted advisor on both our partnership and the sale of the Clinerion business, and helped us to complete this transaction in an expedited timeframe.